<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964767</url>
  </required_header>
  <id_info>
    <org_study_id>SinghRK</org_study_id>
    <nct_id>NCT02964767</nct_id>
  </id_info>
  <brief_title>HIV-Tb Confections Among HIV Patients</brief_title>
  <official_title>Prevalence of HIV-Tb co Infections Among HIV Patients and Their CD4+ T Cell Status-A Single Centre Study in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singh, Ranjan Kumar, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singh, Ranjan Kumar, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cross sectional study would be done for prevalence of HIV-Tb. co infection among patients
      of HIV enrolled at ART centre, Khagaria, India, during June' 2015 to May' 2016. A comparative
      study of CD4 (cluster of differentiation 4) T cell count among HIV-Tb. co infected patient
      and HIV patients would be taken in account.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction

      HIV infection increases the susceptibility of Mycobacterium Tuberculosis (M.Tb.) infection,
      and hastens its progression due to changes in immune status of the patients. In fact,
      tuberculosis is now the most common opportunistic infection in patients, who die from AIDS.
      Immune response in tuberculosis and other infections induces cytokines that enhance
      replication of HIV, and derives the patient to full blown AIDS. the prevalence of HIV/Tb
      co-infections have been reported to 0.4% to 20.1% from different regions of northern part of
      india. India is one of the six countries, those are accounted for 60 percent new cases of
      tuberculosis, and the BRICS countries collectively account for approximately 50 perce

      nt cases of worldwide tuberculosis. The prevalence of multidrug resistant
      tuberculosis(MDR-TB.) is two-threefold higher in HIV co-infected patients; as HIV infected
      people rapidly acquire the active disease including resistant strain of M. Tb. and rapidly
      transmit the disease among population including PLHIV, who in turn, manifest the active drug
      resistant tuberculosis.

      Methods

        -  This is cohort study among patients of HIV, attending ART (Antiretroviral therapy)
           center khagaria, Bihar, India during June' 2015 to May' 2016.

        -  Patients enrolled at the centre were subjected to screening for Mycobacterium
           tuberculosis infection by doing ESR, mantoux test, chest x-ray, sputum examination for
           acid fast bacillus (AFB) and nucleic acid amplification test.

        -  HIV/Tb co infected patients were given cotrimoxazole.

        -  Patients' data-for example, age, sex, co infection with tuberculosis would be recorded.

        -  Sputum positivity, radiological features, and extra pulmonary manifestations would be
           recorded and statistical analysis would be done

        -  Statistical analysis, such as, mean, standard deviation(SD), student T test, p-values
           would be done. P-value significance would be measured at p &lt; .05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center.</measure>
    <time_frame>12 months</time_frame>
    <description>% Prevalence of HIV/Tb. co infections= no.of HIV/Tb. co infection (48)/total no. of enrolled patients of HIV including HIV/Tb. co infections (219) x 100, i.e. 21.9%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing CD4+ T Cell Count in HIV-Tb. and HIV Cases.</measure>
    <time_frame>12 months</time_frame>
    <description>CD4 cell counts of HIV patients and HIV/co infection patients would be analysed by student T test, and p value would be estimated.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">219</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV mono infection</arm_group_label>
    <description>HIV Patients do not have active Mycobacterium Tuberculosis infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-Tb. co infection</arm_group_label>
    <description>Patients with HIV and MycobacteriumTuberculosis co infections</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of HIV+ enrolled ART centre

        Exclusion Criteria:

          -  Lost to follow up patients (LFU)

          -  Patients died before the treatment started

          -  Children below 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjan K Singh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician cum nodal officer, ART centre, Khagaria, India.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ART centre, Sadar Hospital</name>
      <address>
        <city>Khagaria</city>
        <state>Bihar</state>
        <zip>851204</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Festenstein F, Grange JM. Tuberculosis and the acquired immune deficiency syndrome. J Appl Bacteriol. 1991 Jul;71(1):19-30. Review.</citation>
    <PMID>1894579</PMID>
  </reference>
  <reference>
    <citation>Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010 May 15;50 Suppl 3:S201-7. doi: 10.1086/651492. Review.</citation>
    <PMID>20397949</PMID>
  </reference>
  <reference>
    <citation>Global Tuberculosis Report 2016, World Health Organisation, Geneva.</citation>
  </reference>
  <reference>
    <citation>Perrin F, Breen R, Lipman M. : HIV and Tuberculosis co-infection. ABC of HIV and AIDS. Michael W, et al (ed): Wiley-Blackwell, BMJ Publishing Group Limited 6:42-47,2012</citation>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <results_first_submitted>January 23, 2017</results_first_submitted>
  <results_first_submitted_qc>April 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2017</results_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Singh, Ranjan Kumar, M.D.</investigator_affiliation>
    <investigator_full_name>Ranjan Kumar Singh</investigator_full_name>
    <investigator_title>Nodal officer of ART centre, Sadar Hospital.</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV-Tb co infection</keyword>
  <keyword>CD4 Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Epidemiological report</doc_type>
      <doc_url>http://www.who.int</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.Wiley.com</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with HIV infection enrolled at ART centre, Khagaria, India, during June'2015 to May'2016 were recruited.</recruitment_details>
      <pre_assignment_details>patients, who were Lost to Follow Up (LFU), were excluded from study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HIV,</title>
          <description>HIV mono infected patients,</description>
        </group>
        <group group_id="P2">
          <title>HIV/Tb.</title>
          <description>Patients with HIV/Tb. co infection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1.HIV</title>
          <description>patients with mono HIV infections</description>
        </group>
        <group group_id="B2">
          <title>2.HIV/Tb.</title>
          <description>Patients with HIV/Tb. co infections</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.26" spread="12.77"/>
                    <measurement group_id="B2" value="34.97" spread="11.21"/>
                    <measurement group_id="B3" value="33.63" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center.</title>
        <description>% Prevalence of HIV/Tb. co infections= no.of HIV/Tb. co infection (48)/total no. of enrolled patients of HIV including HIV/Tb. co infections (219) x 100, i.e. 21.9%</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevalence of HIV/Tb. co Infection</title>
            <description>Percentage of Tb. co infections among HIV patients enrolled at ART center.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center.</title>
          <description>% Prevalence of HIV/Tb. co infections= no.of HIV/Tb. co infection (48)/total no. of enrolled patients of HIV including HIV/Tb. co infections (219) x 100, i.e. 21.9%</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing CD4+ T Cell Count in HIV-Tb. and HIV Cases.</title>
        <description>CD4 cell counts of HIV patients and HIV/co infection patients would be analysed by student T test, and p value would be estimated.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.HIV</title>
            <description>HIV patients only</description>
          </group>
          <group group_id="O2">
            <title>2.HIV/Tb.</title>
            <description>Patients with HIV/Tb. co infections</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing CD4+ T Cell Count in HIV-Tb. and HIV Cases.</title>
          <description>CD4 cell counts of HIV patients and HIV/co infection patients would be analysed by student T test, and p value would be estimated.</description>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.63" spread="317.49"/>
                    <measurement group_id="O2" value="254.29" spread="218.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.049</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>other opportunistic infections</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV,</title>
          <description>HIV patients</description>
        </group>
        <group group_id="E2">
          <title>HIV/Tb. co Infections</title>
          <description>Patients with HIV-Tb. co infections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="00" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="00" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>tablet default</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>giddiness</sub_title>
                <description>caused by ART drug Efavirenz.</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>this is a cross sectional study; findings are limited to the patients attending ART centre.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ranjan K Singh</name_or_title>
      <organization>SinghRK</organization>
      <phone>91+9431263911</phone>
      <email>dr_ranjankumarsingh@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

